Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer

No evidence is available on the head-to-head comparison of clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) in a real-world setting. We aimed to compare the effectiveness and cost-effectiveness profile of nivolumab, pembro...

Descripción completa

Detalles Bibliográficos
Autores principales: Franchi, Matteo, Pellegrini, Giacomo, Corrao, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025730/
https://www.ncbi.nlm.nih.gov/pubmed/35455486
http://dx.doi.org/10.3390/ph15040489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025730/
https://www.ncbi.nlm.nih.gov/pubmed/35455486
http://dx.doi.org/10.3390/ph15040489

Ejemplares similares